Alexion Higher on Spanish Report, Cited by Analyst, That Amgen Will Make Bid - TheStreet
All 'Alexion Pharmaceuticals' news | Silicon Republic
Alexion Settles With Amgen Over Eculizumab Patents
Alexion wins 3 new Soliris patents as Amgen works on biosimilar of pricey drug | Fierce Pharma
Amgen Drops Alexion Blood Drug IPRs, Gets 2025 License
Alexion Pharmaceuticals: In The News And Moving Higher (NASDAQ:ALXN) | Seeking Alpha
Amgen-Alexion deal rumors resurface, to the delight of investors and analysts | Fierce Pharma
Alexion Pharmaceuticals: Patented Quality at a Great Price | by Shivam Kollur | Medium
Paroxysmal Nocturnal Hemoglobinuria Therapeutics Market Is Booming Worldwide 2022-2028 | Alexion Pharmaceuticals, Akari therapeutics, Apellis Pharmaceuticals, Amgen Inc - Digital Journal
Amgen takes aim at Alexion's patents for Soliris - PMLiVE
Should Amgen Finally Buy Alexion Pharmaceuticals? | The Motley Fool
Amgen Settles With Alexion on Soliris Biosimilar, Dropping Litigation and Getting a Release Date
Could Amgen soften the Neulasta biosimilar blow with an Alexion buy? | Fierce Pharma
Worldwide Orphan Drugs Industry to 2027 - Featuring Alexion Pharmaceuticals, Amgen and Biogen Among Others
Alexion (ALXN) Down 3.2% After Amgen Buys Otezla From Celgene
Amgen
US Biopharma Firm Amgen to Acquire Horizon Therapeutics for $28 Billion | IndustryWeek
Alexion plunges as Amgen challenges Soliris patents
Alexion and Amgen Settle IPRs Over SOLIRIS (eculizumab) - Big Molecule Watch
FDA accepts Alexion's application for next-generation PNH drug - MedCity News
Alexion Settles With Amgen Over Eculizumab Patents
Alexion dodges Soliris biosimilar bullet—for now—with Amgen patent settlement | Fierce Pharma
Xconomy: Patent Challenge to Alexion Proceeds, But No Amgen Biosimilar Yet
Amgen readies case for Soliris copycat as 2025 launch looms
Amgen close to deal to buy Horizon Therapeutics for $20bn | Financial Times
Best Biotechnology Stocks To Watch: Alexion, Merck, Amgen, Emergent | Investing.com
Amgen drug patent challenge slices $2B off Alexion's market cap - Boston Business Journal
Orphan Drugs Market Drivers is Responsible to for Increasing Market Share, Forecast 2028 | Acorda Therapeutics, Actelion Pharmaceuticals Ltd., Amgen, Alexion Pharmaceuticals. - Digital Journal
